Tivic Health Has Partnered With Fletcher Spaght, To Accelerate Development Of Its Commercial Strategy For Non-Invasive Cervical Vagus Nerve Stimulation
Tivic Health Has Partnered With Fletcher Spaght, To Accelerate Development Of Its Commercial Strategy For Non-Invasive Cervical Vagus Nerve Stimulation
Partners with leading growth strategy firm, Fletcher Spaght
與領先的增長策略公司Fletcher Spaght合作
Tivic Health Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS").
Tivic Health Systems, Inc.（"Tivic Health"，納斯達克：TIVC）是一家開發和商業化生物電子醫學技術的健康科技公司，今天宣佈已與Fletcher Spaght（"FSI"）合作，加速發展其非侵入性頸部迷走神經刺激（"ncVNS"）的商業策略。FSI是一家領先的醫療保健增長策略公司。
Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in 2021 to $21.3 billion in 2030, a 10.6% CAGR over the forecast period. Additionally, IDTechEx has forecast peripheral nerve stimulation, the segment targeted by Tivic Health, will grow at 35% CAGR, one of the fastest growth segments in bioelectronic medicine.
Polaris公司市場研究估計，全球迷走神經刺激市場將從2021年的85.9億美元增長到2030年的213億美元，年複合增長率爲10.6%。此外，IDTechEx預測，Tivic Health針對的外周神經刺激領域，將以35%的年複合增長率增長，成爲生物電子醫學領域增長最快的細分市場之一。
譯文內容由第三人軟體翻譯。
